sCD95L in serum after spinal cord injury

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Traumatic spinal cord injury (SCI) is a complex condition with significant impact on neurological function.
• Understanding the biomarkers associated with SCI recovery is crucial for developing effective treatments.
• Previous studies, primarily in animal models, have investigated the role of serum cluster of differentiation 95 ligand (sCD95L) in SCI.

Purpose of the Study:

• To investigate the correlation between serum sCD95L levels and neurological remission in human patients following traumatic SCI.
• To compare these findings with existing data from animal studies on sCD95L and SCI.

Main Methods:

• A prospective observational study was conducted with 45 patients diagnosed with traumatic SCI.
• Patients were categorized into two groups based on neurological outcome: those with remission (G1) and those without (G2).
• Serum sCD95L levels were measured at multiple time points post-admission, including 4, 9, 12 hours, and 1, 3 days, and 1, 2, 4, 8, 12 weeks.

Main Results:

• A significant correlation was observed between neurological remission and sCD95L serum concentrations in human patients.
• Patients with neurological remission (G1) exhibited consistently elevated sCD95L levels compared to those without remission (G2), particularly between 9 hours and 1 month post-injury.
• Significantly different sCD95L values were noted 7 days after injury between the two groups.

Conclusions:

• Contrary to findings in animal studies, higher sCD95L levels are associated with neurological remission in human SCI patients.
• These results suggest that therapies aimed at neutralizing CD95L may not benefit spinal cord-injured patients.
• The study highlights the critical need for careful consideration when extrapolating findings from animal models to human clinical practice.
• Peripheral serum cytokine expression, such as sCD95L, is a valuable indicator for monitoring post-SCI processes in humans.